Originally published by our sister publication Specialty Pharmacy Continuum
By SPC Staff
The FDA approved atidarsagene autotemcel (Lenmeldy, Orchard Therapeutics), the first gene therapy for children with presymptomatic late infantile, presymptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). 
Orchard Therapeutics, which was recently acquired by Kyowa Kirin, set the wholesale acquisition cost (WAC) for the gene therapy at $4.25